384 related articles for article (PubMed ID: 23072611)
21. Development and evaluation of fast-dissolving tablets of meloxicam-β-cyclodextrin complex prepared by direct compression.
Obaidat AA; Obaidat RM
Acta Pharm; 2011 Mar; 61(1):83-91. PubMed ID: 21406346
[TBL] [Abstract][Full Text] [Related]
22. Semi solid matrix formulations of meloxicam and tenoxicam: an in vitro and in vivo evaluation.
Alladi S; Shastri NR
Arch Pharm Res; 2015; 38(5):801-12. PubMed ID: 24752862
[TBL] [Abstract][Full Text] [Related]
23. Study of sodium hyaluronate-based intranasal formulations containing micro- or nanosized meloxicam particles.
Bartos C; Ambrus R; Sipos P; Budai-Szűcs M; Csányi E; Gáspár R; Márki Á; Seres AB; Sztojkov-Ivanov A; Horváth T; Szabó-Révész P
Int J Pharm; 2015 Aug; 491(1-2):198-207. PubMed ID: 26142244
[TBL] [Abstract][Full Text] [Related]
24. Criterion for excipients screening in the development of nanoemulsion formulation of three anti-inflammatory drugs.
Shakeel F
Pharm Dev Technol; 2010; 15(2):131-8. PubMed ID: 19911951
[TBL] [Abstract][Full Text] [Related]
25. Drug-excipient compatibility assessment of solid formulations containing meloxicam.
da Silveira LM; Fiorot AB; Xavier TP; Yoshida MI; de Oliveira MA
Eur J Pharm Sci; 2018 Jan; 112():146-151. PubMed ID: 29174987
[TBL] [Abstract][Full Text] [Related]
26. Self nanoemulsifying granules (SNEGs) of meloxicam: preparation, characterization, molecular modeling and evaluation of in vivo anti-inflammatory activity.
Parekh VJ; Desai ND; Shaikh MS; Shinde UA
Drug Dev Ind Pharm; 2017 Apr; 43(4):600-610. PubMed ID: 28005437
[TBL] [Abstract][Full Text] [Related]
27. Bioequivalence in dogs of a meloxicam formulation administered as a transmucosal oral mist with an orally administered pioneer suspension product.
Lees P; Cheng Z; Keefe TJ; Weich E; Bryd J; Cedergren R; Cozzi E
J Vet Pharmacol Ther; 2013 Feb; 36(1):78-84. PubMed ID: 22533512
[TBL] [Abstract][Full Text] [Related]
28. Role of lipid-based excipients and their composition on the bioavailability of antiretroviral self-emulsifying formulations.
Chudasama A; Patel V; Nivsarkar M; Vasu K; Shishoo C
Drug Deliv; 2015; 22(4):531-40. PubMed ID: 24601856
[TBL] [Abstract][Full Text] [Related]
29. [Stability testing of meloxicam-containing microcomposites for inhalation].
Pomázi A; Ambrus R; Szabóné Révész P
Acta Pharm Hung; 2014; 84(2):55-62. PubMed ID: 25167700
[TBL] [Abstract][Full Text] [Related]
30. Novel milk-based oral formulations: proof of concept.
Charkoftaki G; Kytariolos J; Macheras P
Int J Pharm; 2010 May; 390(2):150-9. PubMed ID: 20117197
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of meloxicam in adult goats: a comparative study of subcutaneous, oral and intravenous administration.
Karademir U; Erdogan H; Boyacioglu M; Kum C; Sekkin S; Bilgen M
N Z Vet J; 2016 May; 64(3):165-8. PubMed ID: 26612429
[TBL] [Abstract][Full Text] [Related]
32. Ravuconazole self-emulsifying delivery system: in vitro activity against
Spósito PÁ; Mazzeti AL; de Oliveira Faria C; Urbina JA; Pound-Lana G; Bahia MT; Mosqueira VF
Int J Nanomedicine; 2017; 12():3785-3799. PubMed ID: 28553114
[TBL] [Abstract][Full Text] [Related]
33. Aqueous stability and oral pharmacokinetics of meloxicam and carprofen in male C57BL/6 mice.
Ingrao JC; Johnson R; Tor E; Gu Y; Litman M; Turner PV
J Am Assoc Lab Anim Sci; 2013 Sep; 52(5):553-9. PubMed ID: 24041210
[TBL] [Abstract][Full Text] [Related]
34. Enhanced oral bioavailability of Wurenchun (Fructus Schisandrae Chinensis extracts) by self-emulsifying drug delivery systems.
Shao B; Tang J; Ji H; Liu H; Liu Y; Zhu D; Wu L
Drug Dev Ind Pharm; 2010 Nov; 36(11):1356-63. PubMed ID: 20849350
[TBL] [Abstract][Full Text] [Related]
35. Enhanced oral bioavailability of etodolac by self-emulsifying systems: in-vitro and in-vivo evaluation.
Barakat NS
J Pharm Pharmacol; 2010 Feb; 62(2):173-80. PubMed ID: 20487196
[TBL] [Abstract][Full Text] [Related]
36. Clinical pharmacokinetics of meloxicam.
Türck D; Busch U; Heinzel G; Narjes H
Arzneimittelforschung; 1997 Mar; 47(3):253-8. PubMed ID: 9105543
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics of oral gabapentin alone or co-administered with meloxicam in ruminant beef calves.
Coetzee JF; Mosher RA; Kohake LE; Cull CA; Kelly LL; Mueting SL; KuKanich B
Vet J; 2011 Oct; 190(1):98-102. PubMed ID: 20869892
[TBL] [Abstract][Full Text] [Related]
38. Formulation and in vitro characterization of a novel solid lipid-based drug delivery system.
Ma H; Chu M; Itagaki K; Xin P; Zhou X; Zhang D; Wang Y; Fu J; Sun S
Chem Pharm Bull (Tokyo); 2014; 62(12):1173-9. PubMed ID: 25450625
[TBL] [Abstract][Full Text] [Related]
39. Studying the effect of lipid chain length on the precipitation of a poorly water soluble drug from self-emulsifying drug delivery system on dispersion into aqueous medium.
Prasad D; Chauhan H; Atef E
J Pharm Pharmacol; 2013 Aug; 65(8):1134-44. PubMed ID: 23837581
[TBL] [Abstract][Full Text] [Related]
40. Characterization and optimization of AMG 517 supersaturatable self-emulsifying drug delivery system (S-SEDDS) for improved oral absorption.
Gao P; Akrami A; Alvarez F; Hu J; Li L; Ma C; Surapaneni S
J Pharm Sci; 2009 Feb; 98(2):516-28. PubMed ID: 18543293
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
